Table of Contents
Introduction
The global Next Generation Sequencing (NGS) market is projected to grow from USD 8 billion in 2022 to around USD 29 billion by 2032, with a CAGR of 14.6% during the forecast period (2023-2032). This growth is fueled by substantial advancements in NGS technology, which enhance the speed, affordability, and accuracy of genetic sequencing. Such improvements are broadening the scope of NGS applications in areas including oncology, genetic disorders, and infectious disease diagnostics, aligning with the increasing demand for precision medicine. This demand drives the need for personalized treatment plans based on individual genetic information, underscoring the critical role of NGS in modern healthcare.
NGS technology is becoming increasingly integral in clinical settings, particularly for diagnosing and monitoring treatments for cancer and infectious diseases. This surge in clinical applications is supported by ongoing enhancements in sequencing capabilities that provide more comprehensive genomic analyses. The sector’s expansion is also propelled by continuous research and development efforts by both corporations and academic institutions. These initiatives aim to discover new applications for NGS and improve the efficiency of existing platforms and bioinformatics tools necessary for managing extensive sequencing data.
Government and institutional backing significantly boosts the NGS market by funding projects that explore genetic factors in health and diseases, fostering further technological adoption. Additionally, major market players like Roche, PerkinElmer, and Agilent Technologies are crucial to this expansion. These companies extend their global reach through strategic initiatives and partnerships, targeting emerging markets eager for advanced medical technologies. Such strategies ensure a wider distribution and adoption of NGS solutions across diverse regions.
Recent developments in the NGS market highlight the dynamic nature of the industry. In August 2024, Bio-Rad Laboratories appointed Jon DiVincenzo as President and COO, poised to steer the company’s expansion in NGS. Earlier in the year, QIAGEN reported a stable financial performance with anticipated continued growth, while Hoffmann-La Roche launched an innovative NGS platform in February 2024 to enhance genetic analysis capabilities. Additionally, the strategic merger forming Velsera from PierianDx, Seven Bridges, and UgenTec in January 2023 has further consolidated capabilities in genomic and clinical data analysis, strengthening the market position.
These strategic moves and technological advancements indicate a robust and evolving NGS market. Companies are not only focusing on innovation but are also restructuring to optimize their operations towards life sciences and diagnostics. This proactive approach in the industry is set to drive significant advancements in healthcare, with NGS at the forefront of revolutionizing medical diagnostics and personalized medicine, illustrating a promising trajectory for the widespread application of genomic technologies.
Key Takeaways
- The Global Next-Generation Sequencing Market was valued at USD 8 billion in 2022.
- It is expected to grow at a 14.6% CAGR from 2023 to 2032.
- By 2032, the market’s estimated incremental revenue will reach USD 29 billion.
- In 2022, targeted sequencing represented the largest technology segment with a 73% revenue share.
- The oncology application was the largest in 2022, comprising 28.5% of global revenue.
- The pre-sequencing workflow generated 56% of the total revenue in 2022.
- Academic research led the end-use segments, earning the highest global revenue in 2022.
- North America was the leading region with a 43% revenue share in 2022.
- Significant growth is anticipated in the Asia Pacific region from 2023 to 2032.
- NGS in oncology helps detect translocations and copy number variants, aiding cancer treatment.
- Rising chronic disease and genetic testing needs are driving NGS demand in diagnostics.
- Next-Generation Sequencing is crucial for identifying drug resistance and response in drug discovery.
- Key Players Includes: Illumina Inc., Hoffman-La Roche, QIAGEN, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, PierianDx Inc., Genomatix GmbH, DNASTAR Inc., Perkin Elme Inc., Eurofins GATC Biotech GmbH, BGI, Precigen Inc., Macrogen Inc., Pillar Biosciences Inc., Agilent Technologies Inc., and Other key players
Next Generation Sequencing Statistics
- Human Genome Project Costs (2004): The project cost approximately $3 billion, marking a major investment in genetic research.
- Modern Whole Exome and Genome Sequencing Costs (2016-2019):
- Whole Exome Sequencing (WES) for infants at a single hospital led to 39 molecular diagnoses out of 278 cases, influencing crucial medical decisions.
- Next-Generation Sequencing (NGS) costs for tumor mutation burden ranged from $438 to $3,700.
- NGS costs for hereditary cancer tests were between $1,722 and $2,249.
- Advancements in Sequencing Technology:
- Initiation of Next-Generation Sequencing (NGS) in 2005 increased throughput by 100 times.
- Single Molecule Real-Time (SMRT) sequencing by Pacific Biosciences started with an 11%-15% error rate in single-pass reads but achieves over 99% accuracy after sufficient sequencing passes.
- Rapid Diagnostic Impact in Clinical Settings:
- Rapid whole-genome sequencing at a children’s hospital successfully diagnosed 20 out of 35 infants with genetic diseases faster than traditional methods.
- Genomic Databases and Their Contributions:
- gnomAD v3.1.1: Includes genomic data from 76,156 individuals, aiding population genetics and disease research.
- gnomAD v2.1.1: Contains data from 125,748 exomes and 15,708 genomes from 141,456 individuals.
- 1000 Genomes Project: Catalogs human genetic variants with a frequency over 1% in global populations.
- HGMD Database: Features extensive mutation data related to hereditary diseases.
- OMIM Database: Covers over 16,000 genes associated with Mendelian disorders.
- ClinVar Database: Stores genetic alterations linked to various diseases.
- InterVar Database: Offers automated assessments of genetic variant pathogenicity based on ACMG guidelines.
- ClinGen Database: Integrates clinical and genetic evidence to classify the pathogenicity of genetic variations.
- COSMIC Database: Contains over 23 million somatic mutations, crucial for understanding cancer development.
- TCGA Database: Provides comprehensive data on human cancers, including genetic variations and clinical data.
Emerging Trends
- Long-read Sequencing Technologies: Next Generation Sequencing (NGS) is advancing with platforms like PacBio Sequel II enhancing long-read sequencing capabilities. This technology significantly improves the analysis of complex genomic regions traditionally challenging for short-read methods. It facilitates a more accurate detection of structural variants and complex genomic rearrangements, pushing the boundaries of genetic research and clinical diagnostics.
- Integration with Multi-omics: NGS is increasingly merging with other omics technologies such as proteomics and metabolomics. This integration provides a holistic view of biological systems and disease mechanisms. Such comprehensive data are pivotal for advancing personalized medicine, offering detailed insights into patient-specific disease processes and potential therapeutic approaches.
- Advancements in Data Analysis: The surge in data volume and complexity from NGS demands enhanced data analysis tools. The focus is on developing sophisticated bioinformatics tools capable of efficiently managing large datasets. These advancements are crucial for improving the accuracy of variant detection and enriching genetic insights, thereby supporting more precise research outcomes and clinical decisions.
- Accessibility and Cost Reduction: NGS technology continues to become more accessible and cost-effective, encouraging its adoption in broader academic and clinical settings. These advancements are democratizing genetic research and patient care, allowing a wider range of professionals to leverage this technology in diverse fields. This trend is crucial for the expansion of genetic insights into everyday healthcare and research environments.
Use Cases
- Clinical Diagnostics: NGS plays a crucial role in the medical field, especially in diagnosing genetic disorders. It identifies inherited mutations and supports personalized medicine approaches. This technology is invaluable in oncology for detecting specific tumor mutations, which aids in tailoring treatment plans for patients.
- Agricultural Improvements: In the agricultural sector, NGS contributes to enhancing crop yields and quality. It provides genetic data that assists in breeding programs, focusing on developing traits such as disease resistance and drought tolerance. This leads to more resilient crop varieties, boosting agricultural productivity.
- Infectious Disease Research: NGS is essential in public health for monitoring and researching infectious diseases. It identifies pathogens, analyzes their evolution, and tracks outbreak patterns. This information is crucial for effective public health responses and strategies to control disease spread.
- Environmental and Conservation Biology: In environmental science, NGS is used for studying biodiversity and conservation efforts. It helps assess the impact of environmental changes on genetic diversity and supports the conservation of endangered species by providing detailed genetic information.
Conclusion
The Next Generation Sequencing (NGS) market is poised for significant growth, driven by the demand for precision medicine and advancements in sequencing technology. As NGS becomes more integrated into clinical and research settings, its impact on healthcare is expanding, particularly in oncology, genetic disorder diagnostics, and infectious disease studies. With substantial support from government and institutional funding, the market is set to broaden its applications and enhance genetic analysis capabilities. Major players like Roche, PerkinElmer, and Agilent Technologies are spearheading this growth through strategic initiatives aimed at capturing emerging markets. Overall, the future of the NGS market looks promising, with ongoing innovations and strategic mergers enhancing its global reach and technological prowess.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
